Research ExplorerPublicationsAcute Myelogenous Leukemia and its Microenvironment: A Molec...

Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation

Standard

Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. / Ghiaur, Gabriel; Wroblewski, Mark; Loges, Sonja.

In: SEMIN HEMATOL, Vol. 52, No. 3, 07.2015, p. 200-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ghiaur, G, Wroblewski, M & Loges, S 2015, 'Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation', SEMIN HEMATOL, vol. 52, no. 3, pp. 200-6. https://doi.org/10.1053/j.seminhematol.2015.03.003

APA

Ghiaur, G., Wroblewski, M., & Loges, S. (2015). Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. SEMIN HEMATOL, 52(3), 200-6. https://doi.org/10.1053/j.seminhematol.2015.03.003

Vancouver

Ghiaur G, Wroblewski M, Loges S. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. SEMIN HEMATOL. 2015 Jul;52(3):200-6. https://doi.org/10.1053/j.seminhematol.2015.03.003

Bibtex

@article{727ab813d9e24f8ab2308d7048256529,
title = "Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation",
abstract = "Survival of patients with acute myelogenous leukemia (AML) depends on our ability to prevent relapse in patients that achieved complete remission after intensive chemotherapy. While studies focusing on the malignant clone brought many advances in understanding AML biology and chemoresistance, little improvement has been made in eliminating the last bastion of malignant cells, the minimal residual disease (MRD). Inspired by Sir Paget's {"}soil and seed{"} hypothesis, it is becoming more clear that there is constant feedback between the malignant clone and the leukemic microenvironment. This {"}molecular conversation{"} dictates AML behavior and holds the key to eliminating MRD. Here we review recent advances in our understanding of how leukemia cells modify their microenvironment and how these changes reinforce AML homeostasis. In addition, we outline current clinical and preclinical efforts to disrupt these interactions and to therapeutically target MRD.",
keywords = "Animals, Bone Marrow, Cell Communication, Humans, Leukemia, Myeloid, Acute, Neoplasm, Residual, Stem Cells, Tumor Microenvironment",
author = "Gabriel Ghiaur and Mark Wroblewski and Sonja Loges",
note = "Copyright {\textcopyright} 2015 Elsevier Inc. All rights reserved.",
year = "2015",
month = jul,
doi = "10.1053/j.seminhematol.2015.03.003",
language = "English",
volume = "52",
pages = "200--6",
journal = "SEMIN HEMATOL",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation

AU - Ghiaur, Gabriel

AU - Wroblewski, Mark

AU - Loges, Sonja

N1 - Copyright © 2015 Elsevier Inc. All rights reserved.

PY - 2015/7

Y1 - 2015/7

N2 - Survival of patients with acute myelogenous leukemia (AML) depends on our ability to prevent relapse in patients that achieved complete remission after intensive chemotherapy. While studies focusing on the malignant clone brought many advances in understanding AML biology and chemoresistance, little improvement has been made in eliminating the last bastion of malignant cells, the minimal residual disease (MRD). Inspired by Sir Paget's "soil and seed" hypothesis, it is becoming more clear that there is constant feedback between the malignant clone and the leukemic microenvironment. This "molecular conversation" dictates AML behavior and holds the key to eliminating MRD. Here we review recent advances in our understanding of how leukemia cells modify their microenvironment and how these changes reinforce AML homeostasis. In addition, we outline current clinical and preclinical efforts to disrupt these interactions and to therapeutically target MRD.

AB - Survival of patients with acute myelogenous leukemia (AML) depends on our ability to prevent relapse in patients that achieved complete remission after intensive chemotherapy. While studies focusing on the malignant clone brought many advances in understanding AML biology and chemoresistance, little improvement has been made in eliminating the last bastion of malignant cells, the minimal residual disease (MRD). Inspired by Sir Paget's "soil and seed" hypothesis, it is becoming more clear that there is constant feedback between the malignant clone and the leukemic microenvironment. This "molecular conversation" dictates AML behavior and holds the key to eliminating MRD. Here we review recent advances in our understanding of how leukemia cells modify their microenvironment and how these changes reinforce AML homeostasis. In addition, we outline current clinical and preclinical efforts to disrupt these interactions and to therapeutically target MRD.

KW - Animals

KW - Bone Marrow

KW - Cell Communication

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Neoplasm, Residual

KW - Stem Cells

KW - Tumor Microenvironment

U2 - 10.1053/j.seminhematol.2015.03.003

DO - 10.1053/j.seminhematol.2015.03.003

M3 - SCORING: Journal article

C2 - 26111467

VL - 52

SP - 200

EP - 206

JO - SEMIN HEMATOL

JF - SEMIN HEMATOL

SN - 0037-1963

IS - 3

ER -